CILTA-CEL EFFICACY AND SAFETY IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER NONCELLULAR ANTI-BCMA IMMUNOTHERAPY

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

Cohen, Adam ^{[2
]}

Cohen, Yael ^{[3
]}

Rodriguez-Otero, Paula ^{[4
]}

Paiva, Bruno ^{[4
]}

van de Donk, Niels ^{[5
]}

Martin, Thomas ^{[6
]}

Suvannasankha, Attaya ^{[7
,8
]}

Madduri, Deepu ^{[9
]}

Corsale, Christina ^{[10
]}

Schecter, Jordan ^{[10
]}

De Braganca, Kevin ^{[10
]}

Jackson, Carolyn ^{[10
]}

Varsos, Helen ^{[10
]}

Deraedt, William ^{[11
]}

Roccia, Tito ^{[12
]}

Mistry, Pankaj ^{[13
]}

Xu, Xiaoying ^{[10
]}

Li, Katherine ^{[14
]}

Zudaire, Enrique ^{[14
]}

Akram, Muhammad ^{[15
]}

Pacaud, Lida ^{[15
]}

Avivi, Irit ^{[3
]}

San-Miguel, Jesus ^{[4
]}

机构：

[1] Hosp Clin Univ Salamanca, Salamanca, Spain

[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[3] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[4] Univ Navarra, Pamplona, Spain

[5] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands

[6] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[7] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA

[8] Roudebush VAMC, Indianapolis, IN USA

[9] Mt Sinai Med Ctr, New York, NY USA

[10] Janssen Res & Dev, Raritan, NJ USA

[11] Janssen Res & Dev, Beerse, Belgium

[12] Janssen Global Serv, Raritan, NJ USA

[13] Janssen Res & Dev, High Wycombe, Bucks, England

[14] Janssen R&D, Spring House, PA USA

[15] Legend Biotech USA, Piscataway, NJ USA

来源：

BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O116

引用

页码：104 / 105

页数：2

共 50 条

[1] Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
Cohen, Adam D.
Mateos, Maria-Victoria
Cohen, Yael C.
Rodriguez Otero, Paula
Paiva, Bruno
Van de Donk, Niels W. C. J.
Martin, Thomas
Suvannasankha, Attaya
Corsale, Christina
Schecter, Jordan M.
De Braganca, Kevin C.
Jackson, Carolyn C.
Varsos, Helen
Deraedt, William
Roccia, Tito
Mistry, Pankaj
Xu, Xiaoying
Li, Katherine
Zudaire, Enrique
Akram, Muhammad
Pacaud, Lida
Avivi, Irit
San-Miguel, Jesus
BLOOD, 2022, 140 : 4646 - 4648
[2] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Cohen, Adam D.
Mateos, Maria-Victoria
Cohen, Yael C.
Rodriguez-Otero, Paula
Paiva, Bruno
van de Donk, Niels W. C. J.
Martin, Thomas
Suvannasankha, Attaya
De Braganca, Kevin C.
Corsale, Christina
Schecter, Jordan M.
Varsos, Helen
Deraedt, William
Wang, Liwei
Vogel, Martin
Roccia, Tito
Xu, Xiaoying
Mistry, Pankaj
Zudaire, Enrique
Akram, Muhammad
Nesheiwat, Tonia
Pacaud, Lida
Avivi, Irit
San-Miguel, Jesus
BLOOD, 2023, 141 (03) : 219 - 230
[3] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment
San-Miguel, Jesus
Mateos, Maria-Victoria
Cohen, Yael C.
Rodriguez-Otero, Paula
Paiva, Bruno
van de Donk, Niels W. C. J.
Martin, Thomas
Abu-Zaid, Mohammad
Corsale, Christina
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Deraedt, William
Wang, Liwei
Roccia, Tito
Li, Claire
Mistry, Pankaj
Xu, Xiaoying
Zudaire, Enrique
Akram, Muhammad
Nesheiwat, Tonia
Pacaud, Lida
Avivi, Irit
Cohen, Adam D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S36
[4] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting antibody-drug conjugate treatment
Cohen, Adam
Mateos, Maria-Victoria
Cohen, Yael
Rodriguez-Otero, Paula
Paiva, Bruno
van de Donk, Niels W. C. J.
Martin, Thomas
Abu-Zaid, Mohammad
Corsale, Christina
Schecter, Jordan
De Braganca, Kevin
Varsos, Helen
Deraedt, William
Wang, Liwei
Roccia, Tito
Li, Claire
Mistry, Pankaj
Xu, Xiaoying
Zudaire, Enrique
Akram, Muhammad
Nesheiwat, Tonia
Pacaud, Lida
Avivi, Irit
San-Miguel, Jesus
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S26 - S27
[5] Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
CIRCULATION, 2024, 150
[6] Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Costa, Luciano J.
Lin, Yi
Cornell, R. Frank
Martin, Thomas
Chhabra, Saurabh
Usmani, Saad Z.
Jagannath, Sundar
Callander, Natalie S.
Berdeja, Jesus G.
Kang, Yubin
Vij, Ravi
Godby, Kelly N.
Malek, Ehsan
Neppalli, Amarendra
Liedtke, Michaela
Fiala, Mark
Tian, Hong
Valluri, Satish
Marino, Jennifer
Jackson, Carolyn C.
Banerjee, Arnob
Kansagra, Ankit
Schecter, Jordan M.
Kumar, Shaji
Hari, Parameswaran
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 326 - 335
[7] Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
Jagannath, Sundar
Jackson, Carolyn C.
Schecter, Jordan M.
Lendvai, Nikoletta
Sun, Huabin
Akram, Muhammad
Patel, Nitin
Martin, Thomas G.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 339 - 350
[8] Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma
dos Santos, Junia Vieira
Melnekoff, David
Aleman, Adolfo
Bhalla, Sherry
Mouhieddine, Tarek H.
Van Oekelen, Oliver
Rajeeve, Sridevi
Upadhyaya, Bhaskar
Ghodke-Puranik, Yogita
Leshchenko, Violetta
Rahman, Adeeb
Afik, Shaked
Lewinsky, Hadas
Thibaud, Santiago
Cho, Hearn Jay
Richter, Joshua
Rodriguez, Cesar
Sanchez, Larysa
Rossi, Adriana C.
Richard, Shambavi
Chari, Ajai
Jagannath, Sundar
Parekh, Samir
Lagana, Alessandro
BLOOD, 2023, 142
[9] CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.
Agha, Mounzer E.
Cohen, Adam D.
Madduri, Deepu
Cohen, Yael C.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Carrasco-Alfonso, Marlene
Akram, Muhammad
Wu, Xiaoling
Nesheiwat, Tonia
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Hansen, Doris K.
Patel, Krina K.
Peres, Lauren C.
Kocoglu, Mehmet H.
Shune, Leyla
Simmons, Gary
Ferreri, Christopher J.
Atrash, Shebli
Parrondo, Ricardo Daniel
Chhabra, Saurabh
Costello, Patrick
Midha, Shonali
Alsina, Melissa
Voorhees, Peter M.
Htut, Myo
Sborov, Douglas W.
Khouri, Jack
Janakiram, Murali
Lin, Yi
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →